Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
== Habitat and distribution == Amanita virosa is found in woodland in late summer and autumn, especially in association with beech and chestnut, but also with pine, spruce, and fir. As with most Amanita species, it forms a mutually beneficial, ectomycorrhizal relationship with the roots of these trees. Amanita virosa was originally described from Sweden and is known throughout Europe, with additional confirmed records from northern Asia (China). The name was formerly used for similar-looking agarics in North America, but research has shown that these American species, including the eastern Amanita bisporigera, the western A. ocreata, and the northern Amanita amerivirosa, are distinct.
Mescaline, also known in chemical terms as 3,4,5-trimethoxyphenethylamine, is a naturally occurring psychedelic drug and alkaloid of the phenethylamine and scaline families found in certain cacti like peyote (Lophophora williamsii) and the San Pedro cactus (Echinopsis pachanoi, others). The drug is used recreationally, spiritually, and medically, with psychedelic effects occurring at doses of 100 to 800 mg (as its hydrochloride salt) orally and it can be used in pure form or in the form of mescaline-containing cacti. Mescaline induces a psychedelic experience characterized by visual changes, altered perception of time, space, and self, synesthesia, and spiritual experiences, with an onset of 30 to 60 minutes, a time to peak of 2 to 4 hours, and a duration that increases with dose and ranges from 6 to 14 hours. Mescaline primarily acts as a partial agonist at serotonin 5-HT2A receptors, with varying affinity and efficacy across multiple other receptors and targets. The serotonin 5-HT2A receptor antagonist ketanserin blocks mescaline's psychoactive effects. Mescaline is a relatively hydrophilic compound structurally related to dopamine, first synthesized in 1919, with numerous synthetic methods and potent analogues developed since. It occurs naturally in various cacti species, with concentrations varying widely, and is biosynthesized in plants from amino acids like phenylalanine and tyrosine. The practice of humans consuming mescaline-containing cacti dates back over 6,000 years.
=== Chemical and molecular properties === A neutral atom has the same number of electrons as protons. Thus different isotopes of a given element all have the same number of electrons and share a similar electronic structure. Because the chemical behaviour of an atom is largely determined by its electronic structure, different isotopes exhibit nearly identical chemical behaviour. The main exception to this is the kinetic isotope effect: due to their larger masses, heavier isotopes tend to react somewhat more slowly than lighter isotopes of the same element. This is most pronounced by far for protium (1H), deuterium (2H), and tritium (3H), because deuterium has twice the mass of protium and tritium has three times the mass of protium. These mass differences also affect the behavior of their respective chemical bonds, by changing the center of gravity (reduced mass) of the atomic systems. However, for heavier elements, the relative mass difference between isotopes is much less so that the mass-difference effects on chemistry are usually negligible. (Heavy elements also have relatively more neutrons than lighter elements, so the ratio of the nuclear mass to the collective electronic mass is slightly greater.) There is also an equilibrium isotope effect.
=== Pharmacodynamics === Dimethocaine and structurally related local anesthetics such as cocaine and procaine inhibit the uptake of dopamine (DA) by blocking dopamine transporters (DAT). The dopamine transporter controls the dynamics of the neurotransmitter dopamine. This neurotransmitter controls many functions including movement, cognition and mood. Drugs such as cocaine and dimethocaine induce dopamine overflow by inhibiting dopamine transporters and thus creating a euphoric effect. In addition to inhibiting dopamine uptake, dimethocaine was also shown to inhibit the binding of CFT, a different dopamine uptake inhibitor. These inhibitory properties are responsible for the stimulatory effects of dimethocaine on the central nervous system. Both in vivo and in vitro measurements of dopamine transporter activity showed that dimethocaine is a potent and efficacious dopaminergic reuptake inhibitor (also called a dopamine indirect agonist). These effects were mainly observed in the nucleus accumbens, a region in the basal forebrain. Comparison of the pharmacological potencies of different local anesthetics revealed the following potency order: cocaine > dimethocaine > tetracaine > procaine > chloroprocaine Furthermore, the administration of dimethocaine has been shown to lead to antinociceptive responses at nontoxic doses in mice. These responses are suggested to be at least partially caused by the effects of dimethocaine on the central nervous system.
Action – Far Cry 3 Artistic Achievement – Journey Audio Achievement – Journey Best Game – Dishonored British Game – The Room Debut Game – The Unfinished Swan Family – Lego Batman 2: DC Super Heroes Game Design – Journey Game Innovation – The Unfinished Swan Mobile & Handheld – The Walking Dead Online – Browser – SongPop Online Multiplayer – Journey Original Music – Journey Performer – Danny Wallace (as the narrator, Thomas Was Alone) Sports/Fitness – New Star Soccer Story – The Walking Dead Strategy – XCOM: Enemy Unknown BAFTA Ones to Watch Award (in association with Dare to Be Digital) – Starcrossed Academy Fellowship – Gabe Newell
Sources: en.wikipedia.org
Pre-formed mediators stored in granules biogenic amines (histamine, serotonin, dopamine) proteases (serine proteases including tryptase and chymase, aspartic acid proteases, cysteine proteases, metalloproteinases including CPA3) proteoglycans (heparin, chondroitin sulfate) cytokines (TNF, IL-4) growth factors (GM-CSF, bFGF, VEGF, NGF) lysosomal enzymes (β-hexosaminidase, β-glucuronidase, CD63) Newly synthesized inflammatory mediators lipid mediators (eicosanoids, thromboxane, LTB4, LTC4, PAF, PGD2) neuropeptides (CRH, VIP) growth factors (PDGF, GnRH) chemokines (MCP-1, eotaxin, TARC, RANTES) cytokines (IL-1, IL-3, IL-6, IL-18, SCF, TGF-β)
Protolichesterinic acid is a naturally occurring γ-lactone compound found in various lichen species. Its structure consists of a combination of a lactone ring with a carboxylic acid group and a long aliphatic side chain. First isolated in the early 20th century, protolichesterinic acid has drawn scientific interest due to its diverse biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. It is also noted for its potential as a therapeutic agent, particularly as a selective inhibitor of the 5-lipoxygenase enzyme, which is implicated in inflammatory diseases. Protolichesterinic acid is typically extracted from lichens such as Cetraria islandica using advanced chromatographic techniques and has been studied for its role in both natural product chemistry and pharmacology.
To determine the concentration of an acid in an aqueous solution, an acid–base titration is commonly performed. A strong base solution with a known concentration, usually NaOH or KOH, is added to neutralize the acid solution according to the color change of the indicator with the amount of base added. The titration curve of an acid titrated by a base has two axes, with the base volume on the x-axis and the solution's pH value on the y-axis. The pH of the solution always goes up as the base is added to the solution.
2026 United States federal budget – $6.8 trillion (submitted 2025 by President Trump) 2025 United States federal budget – $7 trillion (submitted 2024 by President Biden) 2024 United States federal budget – $6.8 trillion (submitted 2023 by President Biden) 2023 United States federal budget – $6.1 trillion (submitted 2022 by President Biden) 2022 United States federal budget – $6.3 trillion (submitted 2021 by President Biden) 2021 United States federal budget – $6.8 trillion (submitted 2020 by President Trump) 2020 United States federal budget – $6.5 trillion (submitted 2019 by President Trump) 2019 United States federal budget – $4.4 trillion (submitted 2018 by President Trump) 2018 United States federal budget – $4.1 trillion (submitted 2017 by President Trump) 2017 United States federal budget – $4.2 trillion (submitted 2016 by President Obama) 2016 United States federal budget – $4 trillion (submitted 2015 by President Obama) 2015 United States federal budget – $3.9 trillion (submitted 2014 by President Obama) 2014 United States federal budget – $3.5 trillion (submitted 2013 by President Obama) 2013 United States federal budget – $3.8 trillion (submitted 2012 by President Obama) 2012 United States federal budget – $3.7 trillion (submitted 2011 by President Obama) 2011 United States federal budget – $3.8 trillion (submitted 2010 by President Obama) 2010 United States federal budget – $3.6 trillion (submitted 2009 by President Obama) 2009 United States federal budget – $3.5 trillion (submitted 2008 by President Bush) 2008 United States federal budget – $2.9 trillion (submitted 2007 by President Bush) 2007 United States federal budget – $2.8 trillion (submitted 2006 by President Bush) 2006 United States federal budget – $2.7 trillion (submitted 2005 by President Bush) 2005 United States federal budget – $2.4 trillion (submitted 2004 by President Bush) 2004 United States federal budget – $2.3 trillion (submitted 2003 by President Bush) 2003 United States federal budget – $2.2 trillion (submitted 2002 by President Bush) 2002 United States federal budget – $2 trillion (submitted 2001 by President Bush) 2001 United States federal budget – $1.9 trillion (submitted 2000 by President Clinton) 2000 United States federal budget – $1.8 trillion (submitted 1999 by President Clinton) 1999 United States federal budget – $1.7 trillion (submitted 1998 by President Clinton) 1998 United States federal budget – $1.7 trillion (submitted 1997 by President Clinton) 1997 United States federal budget – $1.6 trillion (submitted 1996 by President Clinton) 1996 United States federal budget – $1.6 trillion (submitted 1995 by President Clinton) The budget year runs from October 1 to September 30 the following year and is submitted by the President to Congress prior to October for the following year. In this way the budget of 2013 is submitted before the end of September 2012. This means that the budget of 2001 was submitted by Bill Clinton and was in force during most of George W. Bush's first year in office. The budget submitted by George W. Bush in his last year in office was the budget of 2009, which was in force through most of Barack Obama's first year in office. The President's budget also contains revenue and spending projections for the current fiscal year, the coming fiscal years, as well as several future fiscal years. In recent years, the President's budget contained projections five years into the future. The Congressional Budget Office (CBO) issues a "Budget and Economic Outlook" each January and an analysis of the President's budget each March. CBO also issues an updated budget and economic outlook in August. Actual budget data for prior years is available from the Congressional Budget Office; see the "Historical Budget Data" links on the main page of "The Budget and Economic Outlook". and from the Office of Management and Budget (OMB).
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.